Compass Therapeutics (NASDAQ:CMPX) Earns “Buy” Rating from D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX) in a report issued on Wednesday,Benzinga reports. They currently have a $32.00 price target on the stock.

Several other equities analysts have also recently commented on the stock. Leerink Partners cut shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and dropped their target price for the company from $5.00 to $4.00 in a research report on Friday, November 15th. LADENBURG THALM/SH SH upgraded shares of Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price objective for the company in a research report on Monday, September 16th. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Compass Therapeutics in a research note on Monday, November 11th. Finally, Leerink Partnrs lowered Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 15th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $11.80.

Compass Therapeutics Price Performance

Compass Therapeutics stock opened at $1.86 on Wednesday. The firm has a market cap of $255.92 million, a PE ratio of -5.03 and a beta of 0.92. The stock’s fifty day moving average price is $1.57 and its two-hundred day moving average price is $1.44. Compass Therapeutics has a one year low of $0.77 and a one year high of $2.68.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.03. Sell-side analysts expect that Compass Therapeutics will post -0.35 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Compass Therapeutics

Several hedge funds have recently modified their holdings of CMPX. Ground Swell Capital LLC bought a new stake in Compass Therapeutics during the 2nd quarter worth approximately $124,000. Barclays PLC grew its stake in shares of Compass Therapeutics by 195.4% in the third quarter. Barclays PLC now owns 170,245 shares of the company’s stock worth $314,000 after purchasing an additional 112,614 shares during the last quarter. Renaissance Technologies LLC increased its holdings in Compass Therapeutics by 99.7% in the second quarter. Renaissance Technologies LLC now owns 140,600 shares of the company’s stock valued at $141,000 after purchasing an additional 70,200 shares during the period. The Manufacturers Life Insurance Company bought a new position in Compass Therapeutics during the 3rd quarter worth $79,000. Finally, Cubist Systematic Strategies LLC acquired a new position in Compass Therapeutics during the 2nd quarter worth about $41,000. Institutional investors and hedge funds own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.